Navigation Links
Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
Date:4/5/2011

in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.

About Transgene:

Transgene, a member of the Institut Merieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases, and has five compounds in clinical development: TG4010 and JX594 (TG6006) having completed initial phase II trials, TG4001 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with US-based Jennerex Biotherapeutics, Inc., to develop and market JX594 (TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is avai
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors
2. Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
5. Jennerex Appoints Lara Longpre to Chief Operating Officer
6. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
7. Jennerex Announces Presentations at Upcoming Conferences
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... ARBOR, Mich. , Oct. 24, 2014 Advanced ... second quarter (ending September 26, 2014) financial results on Monday, ... will be released after the close of the market and ... discuss the results at 4:30 p.m. EDT on the same ... Richard Kurtz (CEO and Director), Rob Risser ...
(Date:10/25/2014)... , Oct. 24, 2014  The National ... the latest results achieved by Kentucky,s ... The National Precursor Log Exchange ... the point of sale and helps flag meth ... agents often set up NPLEx "watch lists" that ...
(Date:10/25/2014)... DUBLIN , October 24, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/wdq92g/global_and ) has announced the addition ... Industry Report 2014"  report to their ... ,The Global and Chinese Acne Medication Industry ... study on the current state of the ...
Breaking Medicine Technology:Advanced Photonix to Webcast Fiscal 2015 Second Quarter Earnings 2Kentucky's NPLEx Technology Making Significant Progress 2Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3
... SphygmoCor system plays key role in discovery, ... A,new study of more than 10,000 patients, conducted ... United Kingdom using AtCor Medical Holdings,Limited,s SphygmoCor(R) has ... as having "high normal" systolic blood pressure through,traditional ...
... 28 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... oral and,poster presentations on its Cobalamin(TM) technology ... to Clinical Practice, taking,place from May 26-28 ... B12-Polymer Conjugates as Constructs for Targeted Tumor ...
Cached Medicine Technology:New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 2New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 3Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium 2Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium 3
(Date:10/22/2014)... Grants Pass, OR (PRWEB) October 22, 2014 ... while Southern California’s fresh water supply runs dangerously low, ... climate change. Southern Oregon’s rivers, despite the lowest mountain ... fast even in late summer and early autumn.* That ... Urness, authors of the new book “Hiking Southern Oregon,” ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that ... trouble finding time within their busy schedules for exercise and fitness. ... time to get in shape. Here are five ways you can ... , Change Up Your Commute , Consider riding a bike or ... into your daily routine. If you must use your car to ...
(Date:10/22/2014)... Prussia, PA (PRWEB) October 22, 2014 ... recognized as an industry leader with over 25 years ... winning team leader in the areas related to EDI, ... Mr. Carlson is an Editorial Advisory Board member for ... Council Educator. Blue Fin Group is a management ...
(Date:10/22/2014)... By Steven Reinberg ... -- Infants who quickly add weight and length may be ... study suggests. In adults, certain genes have been linked ... promote proportionate gains in fat and lean muscle, the researchers ... be heavier and taller. By ages 2 and 3, however, ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... for health services were meant to motivate health care workers ... in Healthcare. According to researchers, these // ... keep manipulation tactics at bay. ,Gwyn Bevan and ... lauded the target based assessment, but have gone further to ...
... of breast cancer or those who suspect it, feel awkward to ... // ,The Prof says that in the UK alone, the ... and nearly 70 succumb to it. This is also because nearly ... to an irrevocable stage. ,Men should watch out for a ...
... International Journal of Cancer on February 17, 2006 tries to ... the level of physical activity in women. // The prospective ... link. ,Experts felt that since exercise is known ... the gastrointestinal transit time, it might also play a constructive ...
... to reduce smoking amongst children have been lauded with a ... an added thrust to the campaign.// Smoking hampers their ... the drive, by augmenting the anti-smoking budget, Hawaii has regressed ... cigarettes have not been hiked, unfortunately, which might have deterred ...
... Research seems to compliment Acupressure over physical therapy, to ... Taiwan University // have acclaimed Acupressure’s success with statistics ... to physical therapy with the effect lasting up to ... pain were treated with six sessions of acupressure, and ...
... to curb the spread of AIDS/HIV, which is haunting the ... authorities from over 20 different countries in the Asia Pacific ... a universal access to AIDS/HIV treatment and prevention would be ... the failure of the WHO target to expand AIDS treatment ...
Cached Medicine News:Health News:Women, Exercise and Colon Cancer 2
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... USS Sports Medicine POLYSORB Meniscal Stapler XLS ... two resorbable legs of the staple. The ... tissue, specifically the meniscus. The staple is ... derivative of lactic acid and glycolic acids. ...
Medicine Products: